BioAtla | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 22:19
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.27, beating the estimate of USD -0.2967.

EBIT: As of FY2025 Q3, the actual value is USD -13.92 M.

Segment Revenue

  • Collaboration and Other Revenue: $0 for the three and nine months ended September 30, 2025, compared to $11.0 million for the same periods in 2024.

Operational Metrics

  • Research and Development Expense: $9.5 million for the three months ended September 30, 2025, compared to $16.4 million for the same period in 2024. $35.6 million for the nine months ended September 30, 2025, compared to $51.4 million for the same period in 2024.
  • General and Administrative Expense: $4.3 million for the three months ended September 30, 2025, compared to $5.9 million for the same period in 2024. $14.5 million for the nine months ended September 30, 2025, compared to $17.3 million for the same period in 2024.
  • Net Loss: $15.8 million for the three months ended September 30, 2025, compared to $10.6 million for the same period in 2024. $49.8 million for the nine months ended September 30, 2025, compared to $54.9 million for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: - $40.3 million for the nine months ended September 30, 2025, compared to - $55.2 million for the same period in 2024.
  • Net Cash Used in Financing Activities: - $0.4 million for the nine months ended September 30, 2025, compared to $0.2 million provided by financing activities for the same period in 2024.

Unique Metrics

  • Stock-Based Compensation Expense: $4.3 million for the nine months ended September 30, 2025, compared to $7.0 million for the same period in 2024.
  • Loss on Warrant Liability: $2.1 million for the three months ended September 30, 2025, and $0.5 million for the nine months ended September 30, 2025, compared to $0 for the same periods in 2024.

Future Outlook and Strategy

Core Business Focus

  • Clinical Trials: Continue the development of lead product candidates, including mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182, with a focus on completing Phase 2 trials and advancing to later stages of clinical development.
  • Cost Management: Implement initiatives to lower costs and extend cash runway, including a restructuring in March 2025 that included a 30% workforce reduction and a reduction in lease footprint by almost half in June 2025.

Non-Core Business

  • Strategic Collaborations: Explore potential strategic collaborations to accelerate development of certain assets and indications.

Priority

  • Regulatory Approvals: Seek accelerated approval for product candidates where applicable, and continue to engage with the FDA for feedback on clinical trial designs to support potential accelerated approval.
  • Funding: Plan to raise additional capital through equity or debt financings, strategic collaborations, or a combination of these approaches to fund ongoing operations and development programs.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.